Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET
Lists
Only you see this
Abstract
We successfully designed, engineered, and tested a GPC3-targeted 18F-labeled nanobody immunoPET agent, Al[18F]F-ssHN3, demonstrating that it can be used for same-day diagnostic imaging in murine models of liver cancer. Importantly, this agent could address the limitations of current imaging methods by detecting residual disease after thermal ablation and other locoregional therapies.
BibTeX
@inproceedings{fayn2025diagnosis,
author = {Stanley Fayn and Woong Hee Lee and Falguni Basuli and Jianfeng Shi and Hima Makala and Joon‐Yong Chung and Dan Li and Divya Nambiar and Jesse Buffington and Robert Morhard and Colleen P. Olkowski and Orit Jacobson and Bradford J. Wood and Rolf E. Swenson and Ross W. Cheloha and Mitchell Ho and Peter L. Choyke and Freddy E. Escorcia},
title = {{Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET}},
booktitle = {Clinical},
year = {2025},
doi = {10.1158/1078-0432.ccr-25-2587},
}Loading related content...